Stay updated with breaking news from Engineered Elimination. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MRT-6160, a VAV1-directed molecular glue degrader , inhibits colitis disease progression and colon inflammation, lowers inflammatory mucosal cytokines, and reduces expression of IBD-associated genes...
Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors on track; recommended Phase 2 dose expected in Q2 2024 Received US FDA Fast Track Designation for MRT-2359 for previously...
03.01.2024 - BOSTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) - Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief ...
MRT-2359 is under clinical development by Monte Rosa Therapeutics and currently in Phase II for Bladder Cancer.
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the